Literature DB >> 2731776

Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis.

R B Francis1.   

Abstract

The fibrin D-dimer degradation fragment is produced by plasmin degradation of cross-linked fibrin. Elevated plasma D-dimer levels indicate increased plasmin degradation of cross-linked fibrin, and are therefore an indirect indication of increased thrombin activity and fibrin formation. With an ELISA assay sensitive to plasma D-dimer levels of less than 50 ng/ml, elevated levels of D-dimer were found in 23 of 25 subjects with sickle cell disease tested during the steady state, and in all 21 subjects tested serially while hospitalized for painful crisis (total of 40 samples). Mean D-dimer was 79 +/- (SD) 25 ng/ml in 35 normal subjects, 566 +/- 739 ng/ml in sickle cell disease subjects in the steady state, and 1,038 +/- 1,010 ng/ml in sickle cell subjects during painful crisis; these differences were highly significant (p less than 0.001). No correlation was observed between levels of D-dimer in the steady state and the time since the last painful crisis; D-dimer was elevated in all 7 patients tested more than 6 months after their last painful crisis. Most steady-state patients did not have other microvascular occlusive manifestations, such as active leg ulcers or aseptic necrosis of bone, which could explain the increased D-dimer levels observed. It is concluded that increased thrombin activity and fibrin formation are features of steady-state sickle cell disease, and that they further increase during painful crisis. Possible causes and implications of increased thrombin activity and fibrin formation in subjects with sickle cell disease are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2731776     DOI: 10.1159/000215901

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  15 in total

1.  Tissue factor expression by endothelial cells in sickle cell anemia.

Authors:  A Solovey; L Gui; N S Key; R P Hebbel
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

2.  Developing new pharmacotherapeutic approaches to treating sickle-cell disease.

Authors:  Marilyn J Telen
Journal:  ISBT Sci Ser       Date:  2016-11-15

3.  Serum D-dimer concentrations are increased after pediatric traumatic brain injury.

Authors:  Rachel P Berger; Janet Fromkin; Pam Rubin; John Snyder; Rudolph Richichi; Patrick Kochanek
Journal:  J Pediatr       Date:  2014-11-20       Impact factor: 4.406

4.  Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease.

Authors:  R B Francis; L J Haywood
Journal:  J Natl Med Assoc       Date:  1992-07       Impact factor: 1.798

5.  Raised D-dimer levels in acute sickle cell crisis and their correlation with chest X-ray abnormalities.

Authors:  Javeed Dar; Inam Mughal; Hilali Hassan; Taj E Al Mekki; Zivani Chapunduka; Imad S A Hassan
Journal:  Ger Med Sci       Date:  2010-10-08

Review 6.  How I diagnose and treat venous thromboembolism in sickle cell disease.

Authors:  Arun S Shet; Ted Wun
Journal:  Blood       Date:  2018-05-15       Impact factor: 22.113

7.  Inflammation in sickle cell disease.

Authors:  Nicola Conran; John D Belcher
Journal:  Clin Hemorheol Microcirc       Date:  2018       Impact factor: 2.375

8.  Intravascular hemolysis triggers ADP-mediated generation of platelet-rich thrombi in precapillary pulmonary arterioles.

Authors:  Tomasz Brzoska; Ravi Vats; Margaret F Bennewitz; Egemen Tutuncuoglu; Simon C Watkins; Margaret V Ragni; Matthew D Neal; Mark T Gladwin; Prithu Sundd
Journal:  JCI Insight       Date:  2020-07-23

9.  Characterization of the hypercoagulable state in patients with sickle cell disease.

Authors:  Nirmish Shah; Courtney Thornburg; Marilyn J Telen; Thomas L Ortel
Journal:  Thromb Res       Date:  2012-09-07       Impact factor: 3.944

10.  Which adults with sickle cell disease need an evaluation for pulmonary embolism?

Authors:  Nadirah El-Amin; Steven D Lauzon; Paul J Nietert; Julie Kanter
Journal:  Br J Haematol       Date:  2021-09-01       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.